Dolby Family Ventures
Dolby Family Ventures invests in early-stage companies tackling significant science and engineering challenges. They focus on a long-term, collaborative approach, supporting solutions across various sectors including precision neuroscience, life sciences, and climate tech.
United States)Motif Neurotech, Montara Therapeutics, Switch Therapeutics, Ursa Major Technologies, Twelve, DigiLens, Progentos Therapeutics, Monument Biosciences, Magnus Medical, Libra Therapeutics, Cerevance, Cajal Neuroscience, QurAlis, Enclear Therapies, Therini Bio, AZTherapies, NeuroTherapia, Tetra Therapeutics, Alzeca Biosciences, Yumanity Therapeutics, Athira Pharma, Cognition Therapeutics, Cortexyme, PharmatrophiX, MindImmune Therapeutics, Bionaut Labs, Canaery, Cala Health, Salvia BioElectronics, Herophilus, Paradromics, Cogstate, Delix Therapeutics, Vandria, Genemod, Acrigen Biosciences, Arclight Therapeutics, Atomwise, Echo Laboratories, Envisagenics, Hyperfine Research, Zebra Medical Vision, Vium, goBalto, Strateos, Cytovale, Basis Science, NextSense, Transition Biomining, Cquesta, Kebotix, Sharrow Marine, Sepion Technologies, Diamond Age, Calicat, Aether, Kuprion, Moove.ai, AccuKnox, MedCrypt, Vorticity, Sea Machines, NativeWaves, all.health, Atmosic, Niantic Labs, Tempo Automation, Motiv Ring, Chirp Microsystem, UltraLeap, Mojo Vision, Podium Data, Noon Home, 8i, Eyefluence, SoundThinking, Integral Reality Labs, Cato Digital, August, AuthenticVision, Keyssa, Eargo, Wickr, AltSpaceVR, Astro Mechanica, Esper, Cognitive Space, Atomos Nuclear and Space Corporation, Ubotica, Source Energy Company, OKAPI:Orbits, Leo Labs